Here Are Morgan Stanley's Key Oncology Catalysts for 2025
2024's Top and Bottom Nasdaq-100 Performers Includes NVDA, APP, INTC, MRNA, and More
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
S&P 500: 2024 Stars, Flops, and What's Hot for 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
每日空头追踪:Palantir(PLTR.US)卖空量激增5,105.79万,卖空成交比例达23%
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Is Moderna Stock a Buy?
Personalis Rallies Following $50 Million Investment From Merck, Extended Agreement With Moderna
Merck Buys $50 Million of Personalis Stock
Personalis Signs Multi-Year Extension With Moderna To Utilize Its ImmunoID NeXT Platform And Technology For V940/mRNA-4157
California Gov. Newsom Declares State of Emergency Over Bird Flu
Moderna Lowered to Hold at Argus Amid Lower COVID Vaccine Sales, Competitive RSV Market
Moderna Analyst Ratings
アーガスリサーチはモデルナ(MRNA.US)のレーティングを中立に引き下げ
アーガスリサーチのアナリストJasper Hellwegは$Moderna(MRNA.US)$のレーティングを中立に引き下げ。TipRanksのデータによると、このアナリストの最近1年間の的中率は54.4%、平均リターンは6.9%である。注 TipRanksは、金融アナリストの分析データと、アナリストの的中率および平均リターンに関する情報を提供している独立第三者です。提供された情報はあくまで参考情
Worst Performing Stocks for Tax Loss Selling – Wolfe
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
What's Going On With Super Micro Computer Shares Monday?
Super Micro, MicroStrategy, Palantir, Tesla, Broadcom, and More Stock Market Movers
Palantir, MicroStrategy, and Axon Added to the Nasdaq 100 Index